share_log

Expert Outlook: ResMed Through The Eyes Of 9 Analysts

Benzinga ·  Mar 27 14:00

Across the recent three months, 9 analysts have shared their insights on ResMed (NYSE:RMD), expressing a variety of opinions spanning from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings43200
Last 30D10000
1M Ago00000
2M Ago12000
3M Ago21200

Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $203.22, accompanied by a high estimate of $227.00 and a low estimate of $180.00. This current average reflects an increase of 10.52% from the previous average price target of $183.88.

price target chart

Investigating Analyst Ratings: An Elaborate Study

The standing of ResMed among...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment